(BFLY) Butterfly Network - Ratings and Ratios
Ultrasound Device, Probe, Software, Cloud, Education
EPS (Earnings per Share)
Revenue
Dividends
Currently no dividends paid| Risk via 5d forecast | |
|---|---|
| Volatility | 107% |
| Value at Risk 5%th | 146% |
| Relative Tail Risk | -16.91% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.82 |
| Alpha | 5.43 |
| CAGR/Max DD | 0.32 |
| Character TTM | |
|---|---|
| Hurst Exponent | 0.320 |
| Beta | 2.384 |
| Beta Downside | 2.161 |
| Drawdowns 3y | |
|---|---|
| Max DD | 77.55% |
| Mean DD | 46.66% |
| Median DD | 51.04% |
Description: BFLY Butterfly Network December 27, 2025
Butterfly Network, Inc. (NYSE:BFLY) designs, manufactures, and sells handheld ultrasound devices-most notably the Butterfly iQ+ and iQ3-that combine whole-body imaging with a smartphone or tablet interface. The product suite also includes specialty probes (e.g., iQ+ Bladder), a veterinary version (iQ+ Vet), and a subscription-based software platform that offers cloud storage, teleguidance, and educational content through Butterfly Academy and ScanLab. Distribution is mixed: a direct sales force, third-party distributors, and e-commerce channels deliver the hardware and recurring-revenue services to clinicians, health systems, and veterinarians worldwide.
Key quantitative signals (as of FY 2023) include revenue of roughly $210 million, representing a 30 % year-over-year increase, and a gross margin near 70 % driven by the high-margin software subscription model. The point-of-care ultrasound market is projected to grow at a CAGR of 12 % to exceed $5 billion by 2028, buoyed by telehealth adoption, cost-containment pressures in hospitals, and expanding use in primary-care and emergency settings. A material risk factor is the competitive landscape-large incumbents such as Philips and GE are accelerating their own handheld ultrasound rollouts, which could compress pricing or increase customer acquisition costs.
For a deeper quantitative assessment, you might explore ValueRay’s analyst notes on BFLY’s valuation metrics.
Piotroski VR‑10 (Strict, 0-10) 1.5
| Net Income (-79.9m TTM) > 0 and > 6% of Revenue (6% = 5.31m TTM) |
| FCFTA -0.09 (>2.0%) and ΔFCFTA 11.80pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 216.0% (prev 205.6%; Δ 10.42pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA -0.09 (>3.0%) and CFO -24.9m > Net Income -79.9m (YES >=105%, WARN >=100%) |
| NO Net Debt/EBITDA fails (EBITDA <= 0) |
| Current Ratio 4.80 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (252.1m) change vs 12m ago 18.48% (target <= -2.0% for YES) |
| Gross Margin 43.24% (prev 29.60%; Δ 13.65pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 31.86% (prev 28.73%; Δ 3.12pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio -54.79 (EBITDA TTM -69.7m / Interest Expense TTM 1.43m) >= 6 (WARN >= 3) |
Altman Z'' -17.82
| (A) 0.66 = (Total Current Assets 241.4m - Total Current Liabilities 50.3m) / Total Assets 290.0m |
| (B) -2.98 = Retained Earnings (Balance) -863.9m / Total Assets 290.0m |
| warn (B) unusual magnitude: -2.98 — check mapping/units |
| (C) -0.28 = EBIT TTM -78.5m / Avg Total Assets 277.6m |
| (D) -10.03 = Book Value of Equity -863.9m / Total Liabilities 86.2m |
| Total Rating: -17.82 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 34.06
| 1. Piotroski 1.50pt |
| 2. FCF Yield -3.07% |
| 3. FCF Margin -31.12% |
| 4. Debt/Equity 0.10 |
| 5. Debt/Ebitda 1.77 |
| 6. ROIC - WACC (= -43.79)% |
| 7. RoE -37.80% |
| 8. Rev. Trend 59.32% |
| 9. EPS Trend 83.99% |
What is the price of BFLY shares?
Over the past week, the price has changed by +17.58%, over one month by +53.73%, over three months by +116.16% and over the past year by +46.88%.
Is BFLY a buy, sell or hold?
- Strong Buy: 4
- Buy: 0
- Hold: 0
- Sell: 0
- Strong Sell: 0
What are the forecasts/targets for the BFLY price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 4.2 | -15.4% |
| Analysts Target Price | 4.2 | -15.4% |
| ValueRay Target Price | 4.9 | -1.6% |
BFLY Fundamental Data Overview January 12, 2026
P/B = 5.0067
Revenue TTM = 88.4m USD
EBIT TTM = -78.5m USD
EBITDA TTM = -69.7m USD
Long Term Debt = 21.0m USD (from capitalLeaseObligations, last quarter)
Short Term Debt = 2.62m USD (from shortTermDebt, last quarter)
Debt = 21.0m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -123.2m USD (from netDebt column, last quarter)
Enterprise Value = 897.3m USD (1.02b + Debt 21.0m - CCE 144.2m)
Interest Coverage Ratio = -54.79 (Ebit TTM -78.5m / Interest Expense TTM 1.43m)
EV/FCF = -32.60x (Enterprise Value 897.3m / FCF TTM -27.5m)
FCF Yield = -3.07% (FCF TTM -27.5m / Enterprise Value 897.3m)
FCF Margin = -31.12% (FCF TTM -27.5m / Revenue TTM 88.4m)
Net Margin = -90.31% (Net Income TTM -79.9m / Revenue TTM 88.4m)
Gross Margin = 43.24% ((Revenue TTM 88.4m - Cost of Revenue TTM 50.2m) / Revenue TTM)
Gross Margin QoQ = -17.48% (prev 63.68%)
Tobins Q-Ratio = 3.09 (Enterprise Value 897.3m / Total Assets 290.0m)
Interest Expense / Debt = 1.83% (Interest Expense 385.0k / Debt 21.0m)
Taxrate = 21.0% (US default 21%)
NOPAT = -62.0m (EBIT -78.5m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 4.80 (Total Current Assets 241.4m / Total Current Liabilities 50.3m)
Debt / Equity = 0.10 (Debt 21.0m / totalStockholderEquity, last quarter 203.8m)
Debt / EBITDA = 1.77 (negative EBITDA) (Net Debt -123.2m / EBITDA -69.7m)
Debt / FCF = 4.48 (negative FCF - burning cash) (Net Debt -123.2m / FCF TTM -27.5m)
Total Stockholder Equity = 211.3m (last 4 quarters mean from totalStockholderEquity)
RoA = -28.77% (Net Income -79.9m / Total Assets 290.0m)
RoE = -37.80% (Net Income TTM -79.9m / Total Stockholder Equity 211.3m)
RoCE = -33.79% (EBIT -78.5m / Capital Employed (Equity 211.3m + L.T.Debt 21.0m))
RoIC = -29.35% (negative operating profit) (NOPAT -62.0m / Invested Capital 211.3m)
WACC = 14.43% (E(1.02b)/V(1.04b) * Re(14.70%) + D(21.0m)/V(1.04b) * Rd(1.83%) * (1-Tc(0.21)))
Discount Rate = 14.70% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 10.28%
Fair Price DCF = unknown (Cash Flow -27.5m)
EPS Correlation: 83.99 | EPS CAGR: 49.27% | SUE: 0.95 | # QB: 1
Revenue Correlation: 59.32 | Revenue CAGR: 3.36% | SUE: 0.11 | # QB: 0
EPS next Quarter (2026-03-31): EPS=-0.05 | Chg30d=-0.013 | Revisions Net=-1 | Analysts=3
EPS next Year (2026-12-31): EPS=-0.14 | Chg30d=+0.018 | Revisions Net=+1 | Growth EPS=+14.9% | Growth Revenue=+17.3%
Additional Sources for BFLY Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle